FDA approval establishes the only two-drug, non-INSTI, tenofovir-free single-tablet maintenance option for virologically ...

Integrating GLP-1 therapy into primary care enables clinicians to contextualize weight loss alongside cardiometabolic ...

Nearly half of 100 vulnerable medicines have at least one key starting material sourced exclusively from one country, ...

Individualized compounding enables precise dose adjustments, alternative dosage forms, and allergen/excipient avoidance for ...

Maher Masoud, CEO of MaxCyte, discusses the need for developers to come together with platforms.

Documented AI productivity gains include 28% faster target identification, 22% faster biomarker identification, and 20% ...

Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...

In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected ...

Adjusted EPS was $7.23, materially ahead of expectations, and 2026 adjusted EPS guidance was raised to >$18.25, aided by ...

The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump ...